Drug
Nbi 98854 Once Daily
Nbi 98854 Once Daily: highest development phase Phase 1, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-98854 50 mg capsule once daily NCT01910480 | Phase 1 | Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects |
Latest
No recent events.
Follow Nbi 98854 Once Daily on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.